Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  International Business Machines Corp.    IBM

Delayed Quote. Delayed  - 10/21 10:01:12 pm
149.63 USD   -1.25%
10/22 APPLE : Watson Element will be the first `MobileFirst for iOS` educa..
10/22 MICROSOFT : Inside Microsofts quest for a topological quantum comput..
10/22 INTERNATIONAL B : Frost & Sullivan Confer Cloud Company of the Year ..
News SummaryMost relevantAll newsSector news 

International Business Machines Corp. : Memorial Sloan-Kettering Cancer Center, IBM to Collaborate in Applying Watson Technology to Help Oncologists

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2012 | 03:35pm CEST

New York City - 22 Mar 2012: Memorial Sloan-Kettering Cancer Center (MSKCC) and IBM (NYSE: IBM) have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide medical professionals with improved access to current and comprehensive cancer data and practices. The resulting decision support tool will help doctors everywhere create individualized cancer diagnostic and treatment recommendations for their patients based on current evidence.

The initiative will combine the computational power of IBM Watson and its natural language processing ability with MSKCC's clinical knowledge, existing molecular and genomic data and vast repository of cancer case histories, in order to create an outcome and evidence-based decision support system. The goal is to give oncologists located anywhere the ability to obtain detailed diagnostic and treatment options based on updated research that will help them decide how best to care for an individual patient.

The IBM Watson system gained fame by beating human contestants on the television quiz show Jeopardy! It can interpret queries in natural language and uses statistical analysis, advanced analytics and a powerful array of processors to search millions of pages in seconds and deliver evidence-based statistically-ranked responses.

MSKCC's world-renowned oncologists will assist in developing IBM Watson to use a patient's medical information and synthesize a vast array of continuously updated and vetted treatment guidelines, published research and insights gleaned from the deep experience of MSKCC clinicians to provide an individualized recommendation to physicians. The tool will also provide users with a detailed record of the data and evidence used to reach the recommendations.

The need for such an advanced technology arises from the steadily increasing complexity of oncology treatment. Cancers are the second most common cause of death in the U.S., second only to heart disease, and the American Cancer Society projects that 1.6 million new cancer cases will be diagnosed in the U.S. this year* with outcomes varying widely across the country. Cancer is not one disease but some hundreds of sub-types, each with a different genetic fingerprint. Significant discoveries in molecular biology and genetics in the past two decades have delivered new insights into cancer biology and strategies for targeting specific molecular alterations in tumors, but these advances have also ratcheted up the complexity of diagnosing and treating each case. Oncologists and physicians who do not specialize in specific sub-types of cancer face a significant challenge in keeping up with the magnitude of rapidly changing information.

 "The combination of transformational technologies found in Watson with our cancer analytics and decision-making process has the potential to revolutionize the accessibility of information for the treatment of cancer in communities across the country and around the world," said MSKCC President and CEO Craig B. Thompson. "Consistent with our mission, the vision is to help better identify and personalize cancer therapies for each individual patient, no matter where that patient may be receiving care. We also expect tremendous new research opportunities to emerge from this collaboration."

"Memorial Sloan-Kettering's evidence-based clinical approach, scientific acumen, and vast database make it the ideal partner in this ambitious project," said Dr. Martin Kohn, chief medical scientist, IBM. "Cancer care is profoundly complex with continuous clinical and scientific advancements to consider. This field of clinical information, given its importance on both a human and economic level, is exactly the type of grand challenge IBM Watson can help address."

"This comprehensive, evidence-based approach will profoundly enhance cancer care by accelerating the dissemination of practice-changing research at an unprecedented pace," said Dr. Mark G. Kris, Chief, Thoracic Oncology Service at MSKCC and one of the clinicians leading the development effort. He noted that 85 percent of patients with cancer are not treated at specialized medical centers and it can take years for the latest developments in oncology to reach all practice settings.

Development work is already underway for the first applications, which include lung, breast and prostate cancers. The objective is to begin piloting the solutions to a select group of oncologists in late 2012, with wider distribution planned for late 2013. This collaboration complements an earlier announcement by IBM and WellPoint that the parties will focus on putting Watson to work on oncology solutions. 

About Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to www.mskcc.org

*American Cancer Society, Cancer Facts and Figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.

distributed by

This press release was issued by IBM - International Business Machines Corporation and was initially posted at http://www-03.ibm.com/press/us/en/pressrelease/37235.wss . It was distributed, unedited and unaltered, by noodls on 2012-03-22 15:27:46 PM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
10/22 APPLE : Watson Element will be the first `MobileFirst for iOS` education app in ..
10/22 MICROSOFT : Inside Microsofts quest for a topological quantum computer
10/22 INTERNATIONAL BUSINESS MACHINES : Frost & Sullivan Confer Cloud Company of the Y..
10/22 Global Software Testing Market 2016 Accenture, Capgemini, IBM, Wipro.
10/22 INTERNATIONAL BUSINESS MACHINES : IBM Says Enterprise Mac Deployment Saves Money
10/22 INTERNATIONAL BUSINESS MACHINES : Early Blockchain Adopters Kicking Tires
10/21 INTERNATIONAL BUSINESS MACHINES : The Information Technology Industry Council (I..
10/21 WAL MART STORES : Mart partners with IBM to track food shipments in China
10/21 AIR MAURITIUS : takes IBM solution on board
10/21 INDIA : Early-stage startups to get a boost IBM and Indian Angel Network partner..
More news
Sector news : Technology Consulting & Outsourcing Services
10/21DJCyberattack Knocks Out Access to Websites
10/20DJEU Court Adviser Backs Intel Appeal Over $1.17 Billion Fine
10/20 WIPRO : India's Wipro to buy U.S. cloud services company Appirio for $500 millio..
10/18DJSalesforce's M&A Target List Excluded Twitter
10/18DJINTEL : Earnings Rise, but Revenue Outlook Disappoints
More sector news : Technology Consulting & Outsourcing Services
News from SeekingAlpha
10/23 Mixed Messages
10/23 Marc Benioff Is Taking A Page From Larry Ellison's Playbook
10/21 MICROSOFT : Still Undervalued?
10/20 INTEL : Bumper Year Ahead
10/20 IBM's Anecdote Of The Hole
Financials ($)
Sales 2016 79 811 M
EBIT 2016 14 493 M
Net income 2016 11 868 M
Debt 2016 33 764 M
Yield 2016 3,50%
P/E ratio 2016 12,21
P/E ratio 2017 11,80
EV / Sales 2016 2,22x
EV / Sales 2017 2,20x
Capitalization 143 023 M
More Financials
Duration : Period :
International Business Mac Technical Analysis Chart | IBM | US4592001014 | 4-Traders
Full-screen chart
Technical analysis trends INTERNATIONAL BUS...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 25
Average target price 156 $
Spread / Average Target 4,5%
Consensus details
EPS Revisions
More Estimates Revisions
Virginia M. Rometty Chairman, President & Chief Executive Officer
James J. Kavanaugh Senior Vice President-Transformation & Operations
Martin J. Schroeter Chief Financial Officer & Senior Vice President
Jeff Smith Chief Information Officer
Sidney Taurel Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SAMSUNG SDS CO LTD--.--%11 086
DHC SOFTWARE CO., LTD--.--%4 794
More Results